Other languages CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
55.07 ^USD	+2.34%		+2.49%	-12.03%

04-18	Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating	MT
04-17	Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing	04-17
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases	02-21
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023	02-21
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing	02-16
CRISPR Therapeutics to Sell About $280 Million of Common Shares	02-13
Crispr Therapeutics Announces European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY?	02-13
CRISPR Therapeutics Gets FDA Approval For Casgevy to Treat Transfusion-Dependent Beta Thalassemia	01-16
CRISPR Therapeutics Announces U.S. Food and Drug Administration Approval of CASGEVY? for the Treatment of Transfusion-Dependent Beta Thalassemia	01-16
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder	01-16
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery	01-02
CRISPR Therapeutics Chief Medical Officer Phuong Khanh Morrow Resigns	12-20
CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024	12-19
CRISPR Therapeutics AG Adopts Positive Opinion for the Conditional Approval of Casgevy	12-15
Bluebird signs pact with insurer for sickle cell gene therapy	12-14
CRISPR Therapeutics AG, CRISPR Therapeutics Limited, TRACR Hematology Ltd Enters into an Amendment to the Amended and Restated Joint Development and Commercialization Agreement with Vertex Pharmaceuticals ( Europe) Limited	12-13
Vertex y Crispr comercializarán un tratamiento de 2,2 millones de dólares para la anemia falciforme	12-12
Vertex et Crispr vont commercialiser un traitement à 2,2 M$ contre la drépanocytose	12-11
En Direct des Marchés : LVMH, Saint-Gobain, Casino, Manitou, Cigna, Macy's, Pharnext...	12-11
EN DIRECTO DESDE LOS MERCADOS: Nvidia, Microsoft, RWE, LVMH, Apple, Boeing, Tesla, Cigna, Macy's, Uniper, Pharnext...	12-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Other languages

Filters